Dariusz Kowalczyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dariusz Kowalczyk has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Ciborek
Faculty of Medicine and Health Sciences, University of Kalisz, 62-800 Kalisz, Poland
2 shared publications - Jan Matysiak
Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, 61-614 Poznan, Poland
2 shared publications - Jolanta Jaworek
Department of Medicine and Health Care, Faculty of Medicine, University of Applied Sciences in Tarnow (Akademia Tarnowska), ul. Mickiewicza 8, 33-100 Tarnow, Poland
2 shared publications - Agata Światły-Błaszkiewicz
Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Jurasza 2, 85-089 Bydgoszcz, Poland
1 shared publication - Agnieszka Klupczynska
Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Poznań, Poland
1 shared publication - Aleksandra Adamkiewicz
Faculty of Health Sciences, University of Kalisz, 62-800 Kalisz, Poland
1 shared publication
Latest Publications
- Open Access
Contemporary Multimodal Management of Cutaneous Malignancies: Surgery, Radiotherapy, Systemic Therapy, Molecular Targeting and Immunotherapy
Background: The therapeutic management of cutaneous malignancies—cutaneous melanoma, cutaneous squamous-cell carcinoma (cSCC), basal-cell carcinoma (BCC) and Merkel-cell carcinoma (MCC)—has shifted toward multimodal, stage-adapted treatment integrating surgery, radiotherapy, molecularly targeted therapy and immune checkpoint inhibition. Methods: We conducted a structured narrative review with a structured literature search of PubMed/MEDLINE, Scopus and Web of Science (January 2015–6 September 2026), prioritising current clinical practice guidelines, randomised controlled trials and phase II–III studies; landmark older trials were included separately. Synthesis: Surgery with adequate histological margins, including Mohs micrographic surgery where appropriate, remains definitive for localised disease. In resectable macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab with response-driven postoperative management improved event-free survival versus adjuvant nivolumab in NADINA. SWOG S1801 independently demonstrated an event-free-survival advantage for perioperative pembrolizumab over adjuvant-only pembrolizumab in resectable stage III–IV melanoma. In advanced melanoma, dual immune-checkpoint strategies and BRAF/MEK inhibition require patient-specific sequencing; in the European Union, nivolumab plus relatlimab is authorised for first-line advanced melanoma with tumour-cell PD-L1 expression <1%. In high-risk cSCC after surgery and radiotherapy, adjuvant cemiplimab improved disease-free survival. In advanced BCC, Hedgehog-pathway inhibitors remain the principal first systemic option, with anti-PD-1 therapy after HHI failure or intolerance. Clinical implications: Molecular testing should be indication-driven: BRAF V600 is a validated treatment-selecting biomarker, while broader NGS profiling (including NRAS, KIT, NF1, TERT and co-occurring alterations), PD-L1, tumour mutational burden and circulating tumour DNA have context-dependent, supportive or investigational roles. Conclusions: The major unresolved issues are optimal sequencing, response-adapted perioperative treatment, resistance, biomarker validation and treatment of transplant, frail and other under-represented populations.
Open AccessContemporary Multimodal Management of Cutaneous Malignancies: Surgery, Radiotherapy, Systemic Therapy, Molecular Targeting and Immunotherapy
Background: The therapeutic management of cutaneous malignancies—cutaneous melanoma, cutaneous squamous-cell carcinoma (cSCC), basal-cell carcinoma (BCC) and Merkel-cell carcinoma (MCC)—has shifted toward multimodal, stage-adapted treatment integrating surgery, radiotherapy, molecularly targeted therapy and immune checkpoint inhibition. Methods: We conducted a structured narrative review with a structured literature search of PubMed/MEDLINE, Scopus and Web of Science (January 2015–6 September 2026), prioritising current clinical practice guidelines, randomised controlled trials and phase II–III studies; landmark older trials were included separately. Synthesis: Surgery with adequate histological margins, including Mohs micrographic surgery where appropriate, remains definitive for localised disease. In resectable macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab with response-driven postoperative management improved event-free survival versus adjuvant nivolumab in NADINA. SWOG S1801 independently demonstrated an event-free-survival advantage for perioperative pembrolizumab over adjuvant-only pembrolizumab in resectable stage III–IV melanoma. In advanced melanoma, dual immune-checkpoint strategies and BRAF/MEK inhibition require patient-specific sequencing; in the European Union, nivolumab plus relatlimab is authorised for first-line advanced melanoma with tumour-cell PD-L1 expression <1%. In high-risk cSCC after surgery and radiotherapy, adjuvant cemiplimab improved disease-free survival. In advanced BCC, Hedgehog-pathway inhibitors remain the principal first systemic option, with anti-PD-1 therapy after HHI failure or intolerance. Clinical implications: Molecular testing should be indication-driven: BRAF V600 is a validated treatment-selecting biomarker, while broader NGS profiling (including NRAS, KIT, NF1, TERT and co-occurring alterations), PD-L1, tumour mutational burden and circulating tumour DNA have context-dependent, supportive or investigational roles. Conclusions: The major unresolved issues are optimal sequencing, response-adapted perioperative treatment, resistance, biomarker validation and treatment of transplant, frail and other under-represented populations.
- Open Access
Epidemiology of Non-Melanoma Skin Cancer in Europe over the Last Decade: A Systematic Review
Background: Non-melanoma skin cancer (NMSC), principally basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), is incompletely captured by cancer surveillance. Objective: To synthesize European epidemiological evidence, with Poland considered in this context. Methods: PubMed/MEDLINE, Scopus, and Web of Science were searched for publications dated 1 January 2015–31 March 2026, supplemented by registry resources and reference-list searching. Additional eligibility checks during manuscript revision continued until 30 August 2026. The publication-date criterion was distinct from the observation periods of source data. Source-level methodological appraisal informed a descriptive synthesis. Results: The consolidated selection record comprised 198 records, 165 screened records, 61 full-text assessments, 37 full-text exclusions, and 24 included sources. Several registry-based studies reported increasing BCC or cSCC incidence in defined populations. Model-based age-standardized trends varied by geography, sex, age, and observation period. These results do not establish a uniform European increase. Polish estimates were affected by histological aggregation and incomplete ascertainment. Selected pandemic-period studies reported fewer diagnoses or changes in the treated case mix; these findings do not establish a Europe-wide decline in biological incidence or subsequent rebound. Conclusions: NMSC creates a substantial and incompletely measured European burden. Histology-specific registration, explicit multiple-primary counting rules, and improved outpatient capture are priorities for interpreting trends and planning care.
Open AccessEpidemiology of Non-Melanoma Skin Cancer in Europe over the Last Decade: A Systematic Review
Background: Non-melanoma skin cancer (NMSC), principally basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), is incompletely captured by cancer surveillance. Objective: To synthesize European epidemiological evidence, with Poland considered in this context. Methods: PubMed/MEDLINE, Scopus, and Web of Science were searched for publications dated 1 January 2015–31 March 2026, supplemented by registry resources and reference-list searching. Additional eligibility checks during manuscript revision continued until 30 August 2026. The publication-date criterion was distinct from the observation periods of source data. Source-level methodological appraisal informed a descriptive synthesis. Results: The consolidated selection record comprised 198 records, 165 screened records, 61 full-text assessments, 37 full-text exclusions, and 24 included sources. Several registry-based studies reported increasing BCC or cSCC incidence in defined populations. Model-based age-standardized trends varied by geography, sex, age, and observation period. These results do not establish a uniform European increase. Polish estimates were affected by histological aggregation and incomplete ascertainment. Selected pandemic-period studies reported fewer diagnoses or changes in the treated case mix; these findings do not establish a Europe-wide decline in biological incidence or subsequent rebound. Conclusions: NMSC creates a substantial and incompletely measured European burden. Histology-specific registration, explicit multiple-primary counting rules, and improved outpatient capture are priorities for interpreting trends and planning care.
- Open Access
- 17 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1715
Lower Sphingomyelin SM 42:1 Plasma Level in Coronary Artery Disease—Preliminary Study
Coronary artery atherosclerosis is a common condition characterized by different symptomatology and incidences of risk factors. The disease manifestation may differ; therefore, proper diagnosis is essential. The preventive, diagnostic, and therapeutic arms are still developing to improve patient outcomes. Among diagnostic steps, the non-invasive tools for evaluating non-classical factors related to metabolomic profiles are gaining attention. The aim of this study was to investigate possible metabolic profiling differences between patients with chronic coronary artery disease (CAD) and a control group based on plasma sphingomyelin levels. The study group consisted of 23 patients (72% male, median age of 69 (63–72) years) presenting with chronic coronary syndrome and confirmed epicardial disease in coronary angiography and 15 patients (33% male, median age of 70 (64–72) years) with normal angiographic results. Clinical data were recorded, and blood samples were collected for standard biochemical laboratory assessment and metabolomic profiling. The plasma sphingomyelin levels were evaluated in patients with different degrees of coronary artery atherosclerosis involvement. In addition, the severity of the epicardial disease was estimated by the Gensini Score. The study subgroups did not differ in terms of age (p = 0.765) and co-morbidities, though the male sex was more common in the CAD group (p = 0.007). The analysis revealed significant differences regarding neutrophil count (p = 0.014), neutrophil-to-lymphocyte ratio (NLR) (p = 0.016), and high-density lipoprotein (HDL) (p = 0.003). Among different plasma sphingomyelin species, there was a significant difference in plasma SM42:1 level (16.2 (14.2–19.1) vs. 20.8 (18.9–21.7) (p = 0.044) between the CAD and control groups, respectively. The SM 42:1 plasma level was independent of the number of involved epicardial arteries (p = 0.109). However, Spearman correlations tests were performed between the SM 42:1 plasma level and the number of coronary arteries diagnosed with atherosclerosis disease (rho = −0.356, p = 0.014) and the severity of the disease measured by the Gensini Score (rho = −0.403, p = 0.006). There was no correlation between plasma sphingomyelin levels and NLR (Spearman’s rho = −0.135, p = 0.420), suggesting a lack of inflammatory associations. Further, sphingomyelins showed no relationship with coronary artery disease risk factors such as dyslipidemia and diabetes. Lower plasma SM 42:1 levels were revealed in the CAD group compared with the control group, indicating a possible significance of sphingomyelin 42:1 in coronary artery disease progression.
- 17 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1715
Open AccessLower Sphingomyelin SM 42:1 Plasma Level in Coronary Artery Disease—Preliminary Study
Coronary artery atherosclerosis is a common condition characterized by different symptomatology and incidences of risk factors. The disease manifestation may differ; therefore, proper diagnosis is essential. The preventive, diagnostic, and therapeutic arms are still developing to improve patient outcomes. Among diagnostic steps, the non-invasive tools for evaluating non-classical factors related to metabolomic profiles are gaining attention. The aim of this study was to investigate possible metabolic profiling differences between patients with chronic coronary artery disease (CAD) and a control group based on plasma sphingomyelin levels. The study group consisted of 23 patients (72% male, median age of 69 (63–72) years) presenting with chronic coronary syndrome and confirmed epicardial disease in coronary angiography and 15 patients (33% male, median age of 70 (64–72) years) with normal angiographic results. Clinical data were recorded, and blood samples were collected for standard biochemical laboratory assessment and metabolomic profiling. The plasma sphingomyelin levels were evaluated in patients with different degrees of coronary artery atherosclerosis involvement. In addition, the severity of the epicardial disease was estimated by the Gensini Score. The study subgroups did not differ in terms of age (p = 0.765) and co-morbidities, though the male sex was more common in the CAD group (p = 0.007). The analysis revealed significant differences regarding neutrophil count (p = 0.014), neutrophil-to-lymphocyte ratio (NLR) (p = 0.016), and high-density lipoprotein (HDL) (p = 0.003). Among different plasma sphingomyelin species, there was a significant difference in plasma SM42:1 level (16.2 (14.2–19.1) vs. 20.8 (18.9–21.7) (p = 0.044) between the CAD and control groups, respectively. The SM 42:1 plasma level was independent of the number of involved epicardial arteries (p = 0.109). However, Spearman correlations tests were performed between the SM 42:1 plasma level and the number of coronary arteries diagnosed with atherosclerosis disease (rho = −0.356, p = 0.014) and the severity of the disease measured by the Gensini Score (rho = −0.403, p = 0.006). There was no correlation between plasma sphingomyelin levels and NLR (Spearman’s rho = −0.135, p = 0.420), suggesting a lack of inflammatory associations. Further, sphingomyelins showed no relationship with coronary artery disease risk factors such as dyslipidemia and diabetes. Lower plasma SM 42:1 levels were revealed in the CAD group compared with the control group, indicating a possible significance of sphingomyelin 42:1 in coronary artery disease progression.
- Open Access
Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. The risk of disease increases with age, as most CRC patients are over 50 years old. Due to the progressive aging of societies in high-income countries, the problem of CRC will increase. This makes the development of new early detection methods and the implementation of effective screening programs crucial. Key areas of focus include raising population awareness about the importance of screening, educating high-risk populations, and improving and developing early diagnostic methods. The primary goal of this review is to provide a concise overview of recent trends and progress in CRC secondary prevention based on available information from clinical trials.
Open AccessCurrent Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. The risk of disease increases with age, as most CRC patients are over 50 years old. Due to the progressive aging of societies in high-income countries, the problem of CRC will increase. This makes the development of new early detection methods and the implementation of effective screening programs crucial. Key areas of focus include raising population awareness about the importance of screening, educating high-risk populations, and improving and developing early diagnostic methods. The primary goal of this review is to provide a concise overview of recent trends and progress in CRC secondary prevention based on available information from clinical trials.
- Open Access
Pesticides in Honeybee Products—Determination of Pesticides in Bee Pollen, Propolis, and Royal Jelly from Polish Apiary
The bioaccumulation of pesticides in honeybee products (HBPs) should be studied for a number of reasons. The presence of pesticides in HBPs can provide new data on the risk related to the use of pesticides and their role in bee colony losses. Moreover, the degree of contamination of HBPs can lower their quality, weaken their beneficial properties, and, in consequence, may endanger human health. The aim of this study was to quantify a broad range of pesticide residues in three different HBPs—bee pollen, propolis, and royal jelly. Samples were collected in the years 2017–2019 from the apiary in west-central Poland. Bee products were analyzed for the presence of over 550 pesticides using the QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method. Twenty-nine of the contaminants were quantified at least in one of the samples. Nine of them exceeded the maximum residue levels for honey. It should be noted that any dose of pesticides can cause a health hazard due to toxicity, since these substances may act synergistically. This current study revealed the high need for the pesticide monitoring of HBPs and proved that there is a need to expand the European Union Pesticides Database to include more HBPs.
Open AccessPesticides in Honeybee Products—Determination of Pesticides in Bee Pollen, Propolis, and Royal Jelly from Polish Apiary
The bioaccumulation of pesticides in honeybee products (HBPs) should be studied for a number of reasons. The presence of pesticides in HBPs can provide new data on the risk related to the use of pesticides and their role in bee colony losses. Moreover, the degree of contamination of HBPs can lower their quality, weaken their beneficial properties, and, in consequence, may endanger human health. The aim of this study was to quantify a broad range of pesticide residues in three different HBPs—bee pollen, propolis, and royal jelly. Samples were collected in the years 2017–2019 from the apiary in west-central Poland. Bee products were analyzed for the presence of over 550 pesticides using the QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method. Twenty-nine of the contaminants were quantified at least in one of the samples. Nine of them exceeded the maximum residue levels for honey. It should be noted that any dose of pesticides can cause a health hazard due to toxicity, since these substances may act synergistically. This current study revealed the high need for the pesticide monitoring of HBPs and proved that there is a need to expand the European Union Pesticides Database to include more HBPs.
- Open Access
- 28 June 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (13) , 4639
Cervical Cancer Mortality in East-Central European Countries
Changes that took place in Europe in the early 1990s had an impact on health-associated issues. They were an impulse for the changes in healthcare systems and, consequently, also for the changes in cancer control programmes. Those changes also had an effect on mortality rates due to cervical cancer (CC). Therefore, the aim of this study is to analyse CC mortality trends in east-central Europe after 1990. Data on deaths due to CC were retrieved from the WHO Mortality Database. Trends in east-central European countries between 1990 and 2017 were assessed using Joinpoint Regression Program software. CC mortality decreased in the majority of analysed countries. However, an increase was observed in Latvia and Bulgaria. Despite decreasing mortality in the majority of the analysed countries, significant differences were observed. In order to improve the epidemiological situation, effective early detection programmes for cervical cancer ought to be rearranged and based not only on pap smears but also on molecular methods, as well as on introducing widespread programmes of vaccination against HPV.
- 28 June 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (13) , 4639
Open AccessCervical Cancer Mortality in East-Central European Countries
Changes that took place in Europe in the early 1990s had an impact on health-associated issues. They were an impulse for the changes in healthcare systems and, consequently, also for the changes in cancer control programmes. Those changes also had an effect on mortality rates due to cervical cancer (CC). Therefore, the aim of this study is to analyse CC mortality trends in east-central Europe after 1990. Data on deaths due to CC were retrieved from the WHO Mortality Database. Trends in east-central European countries between 1990 and 2017 were assessed using Joinpoint Regression Program software. CC mortality decreased in the majority of analysed countries. However, an increase was observed in Latvia and Bulgaria. Despite decreasing mortality in the majority of the analysed countries, significant differences were observed. In order to improve the epidemiological situation, effective early detection programmes for cervical cancer ought to be rearranged and based not only on pap smears but also on molecular methods, as well as on introducing widespread programmes of vaccination against HPV.